Status:
COMPLETED
Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Mt. Sinai Medical Center, Miami
Collaborating Sponsors:
Sanofi-Synthelabo
Genentech, Inc.
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The combination of oxaliplatin and gemcitabine has proven activity in advanced non-small cell lung cancer (NSCLC). Due to its favorable toxicity profile, this combination is optimal for adding new age...
Detailed Description
STUDY OBJECTIVES: Primary: To determine the overall time to progression of the combination regimen of Gemcitabine, Oxaliplatin and Bevacizumab as first-line treatment in patients with Stage IIIB and...
Eligibility Criteria
Inclusion
- Confirmed non-small cell lung cancer, EXCEPT squamous cell cancer
- Stage IIIB or IV disease
- ECOG PS 0-1
- No prior treatment
- No brain metastases
- Must have measurable disease
Exclusion
- Deep vein thromboses or pulmonary embolus within 1 year
- History of gross hemoptysis
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00217282
Start Date
June 1 2004
End Date
March 1 2008
Last Update
May 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140